Company / Accounts Receivable
Insight Molecular Diagnostics Inc. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.1M
FY2025
5-year range
$484.0K / $2.0M
FY2021-FY2025
Trend
-30.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 6 years, ranging from $203,000 in FY2020 to $2M in FY2022.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of +40.9%.
Improved from $484,000 to $1M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -17.5%
- 5-Year CAGR
- +40.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +40.9%, indicating consistent growth.
- In FY2025, accounts receivable decreased 30.1% year-over-year.
- Peak accounts receivable was recorded in FY2022.
- Lowest accounts receivable in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | -30.1% |
| FY2024 | $1.6M | +233.3% |
| FY2023 | $484.0K | -75.9% |
| FY2022 | $2.0M | +40.0% |
| FY2021 | $1.4M | +607.9% |
| FY2020 | $203.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026